Clik here to view.
BGI Releases 1st Panoramic Atlases of Life
SHENZHEN, China International scientists led by China’s BGI•Research released the world’s first panoramic spatial atlases of life on May 4, examining the cellular dynamics of organisms at different...
View ArticleClik here to view.
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND...
INGELHEIM, Germany & SINGAPORE Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim...
View ArticleClik here to view.
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor...
ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass. Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms...
View ArticleClik here to view.
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient enrollment in the Phase 2a clinical trial of...
View ArticleClik here to view.
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in...
TOKYO & MUNICH & BASKING RIDGE, N.J. New data from Daiichi Sankyo’s (TSE: 4568) patritumab deruxtecan (HER3-DXd) showed clinically meaningful and durable responses in two early-stage trials...
View ArticleClik here to view.
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American...
SAN DIEGO & TOKYO MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global...
View ArticleClik here to view.
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs....
TOKYO & MUNICH & BASKING RIDGE, N.J. Detailed positive results from the pivotal DESTINY-Breast04 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated superior and...
View ArticleClik here to view.
Latest Data of InnoCare’s Orelabrutinib for the Treatment of SLE Presented at...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that Professor Zhanguo Li, the leading PI, has presented latest data of BTK inhibitor orelabrutinib for the...
View ArticleClik here to view.
LUCA Science Raises ¥3.86 Billion ($30.3 Million) in Oversubscribed Series B...
TOKYO LUCA Science, a global innovator in the development of a novel class of mitochondria biopharmaceutical agents, today announced the closing of a ¥3.86 billion (USD 30.3 million) oversubscribed...
View ArticleClik here to view.
Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb...
SEOUL, South Korea & NESS ZIONA, Israel Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody...
View ArticleClik here to view.
Parse Biosciences Announces Partnership with Molecular Diagnostics Korea
SEATTLE Parse Biosciences, a leading provider of scalable single-cell sequencing solutions, today announced a partnership with Molecular Diagnostics Korea (MDxK) that will expand its presence in...
View ArticleClik here to view.
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022...
BEIJING Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster Presentation 1: Phase I results of...
View ArticleClik here to view.
Genexine reports encouraging top-line results of the Phase 1b/2 clinical...
SEOUL, South Korea Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet...
View ArticleClik here to view.
athenahealth and Smile Foundation Partnership Reaches Key Milestone
WATERTOWN, Mass. athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, and Smile Foundation today announced that through...
View ArticleClik here to view.
The Lancet Publication Shows Benefits of PharmaJet Needle-free delivery for...
GOLDEN, Colo. PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that...
View ArticleClik here to view.
EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for...
SHANGHAI & SUZHOU, China EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibody development, today announced that the U.S. Food and Drug...
View ArticleClik here to view.
パース・バイオサイエンシズがモレキュラー・ダイアグノスティクス・コリアとの提携を発表
シアトル （ビジネスワイヤ） — 拡張性のあるシングルセルシーケンシングソリューションを提供する一流企業であるパース・バイオサイエンシズは本日、モレキュラー・ダイアグノスティクス・コリア（MDxK）と提携したと発表しました。この提携では、韓国で当社のEvercode™ホールトランスクリプトーム製品群全体と細胞・核固定キットを提供することで、アジアでのプレゼンスを拡大していきます。...
View ArticleClik here to view.
Clik here to view.
New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022
TAIPEI PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology...
View ArticleClik here to view.
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will participate in one-on-one partnering...
View Article